Source: Current colorectal cancer reports. Unidade: FM
Subjects: NEOPLASIAS COLORRETAIS, METÁSTASE NEOPLÁSICA, ANTICORPOS MONOCLONAIS, QUIMIOTERAPIA (EFEITOS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRAGHIROLI, Maria Ignez et al. Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same?. Current colorectal cancer reports, v. 9, n. 4, p. 317-325, 2013Tradução . . Disponível em: https://doi.org/10.1007/s11888-013-0187-0. Acesso em: 12 jun. 2024.APA
Braghiroli, M. I., Riechelmann, R. P., Sabbaga, J., & Hoff, P. M. G. (2013). Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same? Current colorectal cancer reports, 9( 4), 317-325. doi:10.1007/s11888-013-0187-0NLM
Braghiroli MI, Riechelmann RP, Sabbaga J, Hoff PMG. Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same? [Internet]. Current colorectal cancer reports. 2013 ; 9( 4): 317-325.[citado 2024 jun. 12 ] Available from: https://doi.org/10.1007/s11888-013-0187-0Vancouver
Braghiroli MI, Riechelmann RP, Sabbaga J, Hoff PMG. Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same? [Internet]. Current colorectal cancer reports. 2013 ; 9( 4): 317-325.[citado 2024 jun. 12 ] Available from: https://doi.org/10.1007/s11888-013-0187-0